ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Eli Lilly reports Alzheimer’s imaging solution Amyvid recommended for approval in Europe

October 19, 2012 10:56 am by | 1 Comments

medical devices in Eruope cardiac medical devices remote monitoring

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, recommending approval of Amyvid (Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Paul Quintaro,

Visit website | More posts by Author

1 comments

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
Fresno seeks to cut city’s 20% asthma rate via social-impact bond that pays for success
Close